

Financial news for NBIX dated on 2020-06-10: Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to \$134

Financial news for NBIX dated on 2020-06-09: Benzinga's Top Upgrades, Downgrades For June 9, 2020

Financial news for NBIX dated on 2020-06-09: Wedbush Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of \$147

Financial news for NBIX dated on 2020-06-08: Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

Financial news for NBIX dated on 2020-06-07: The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage

Financial news for NBIX dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for NBIX dated on 2020-05-30: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Financial news for NBIX dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for NBIX dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NBIX dated on 2020-05-20: The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Financial news for NBIX dated on 2020-05-19: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NBIX dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for NBIX dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for NBIX dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for NBIX dated on 2020-05-12: Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy

Financial news for NBIX dated on 2020-05-11: Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy

Financial news for NBIX dated on 2020-05-07: Neurocrine Biosciences Announces New Data Published from Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders

Financial news for NBIX dated on 2020-05-07: Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to \$123

Financial news for NBIX dated on 2020-05-07: Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to \$105

Financial news for NBIX dated on 2020-05-07: Barclays Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to \$108

Financial news for NBIX dated on 2020-05-07: Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to \$120

Financial news for NBIX dated on 2020-05-06: Neurocrine Biosciences Q1 EPS \$0.390 Misses \$0.540 Estimate, Sales \$237.100M Beat \$223.870M Estimate

Financial news for NBIX dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for NBIX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for NBIX dated on 2020-04-27: Neurocrine Biosciences shares are trading higher after the company announced that the FDA approved its ONGENTYS as an add on treatment for patients with Parkinson's disease experiencing "off" episodes.

Financial news for NBIX dated on 2020-04-27: Neurocrine Biosciences Announces FDA

Approval Of Once-Daily ONGENTYS As An Add-On Treatment For Patients With Parkinson's Disease Experiencing 'Off' Episodes

Financial news for NBIX dated on 2020-04-27: FDA Site Shows Approval For Neurocrine Biosciences' Ongentys

Financial news for NBIX dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for NBIX dated on 2020-04-13: Oppenheimer Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to \$130

Financial news for NBIX dated on 2020-04-03: Voyager Therapeutics Reports It, Collaborator Neurocrine Biosciences Temporarily Paused Screening Of New Patients In RESTORE-1 Trial; Will Resume When Cos. Can Determine Screening Will Be Safety, Effective

Financial news for NBIX dated on 2020-03-31: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for NBIX dated on 2020-03-17: 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades

Financial news for NBIX dated on 2020-03-06: Benzinga's Top Upgrades, Downgrades For March 6, 2020

Financial news for NBIX dated on 2020-03-06: Citigroup Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces \$124 Price Target

Financial news for NBIX dated on 2020-02-24: William Blair Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces \$116 Price Target

Financial news for NBIX dated on 2020-02-06: Mizuho Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces \$107 Price Target

Financial news for NBIX dated on 2020-02-05: Mizuho Initiates Coverage On Pfizer, Evolus, Karuna Therapeutics With Buy Ratings, Neurocrine Biosciences, Sage Therapeutics With Neutrals

Financial news for NBIX dated on 2020-02-05: H.C. Wainwright Reiterates Buy on Neurocrine Biosciences, Raises Price Target to \$125

Financial news for NBIX dated on 2020-02-04: Neurocrine Biosciences Q4 EPS \$0.35 Misses \$0.75 Estimate, Sales \$237.9M Beat \$230.94M Estimate

Financial news for NBIX dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for NBIX dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for NBIX dated on 2020-01-17: Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to \$121

Financial news for NBIX dated on 2020-01-13: Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to \$132

Financial news for NBIX dated on 2020-01-10: Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

Financial news for NBIX dated on 2019-12-17: Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Raises Price Target to \$120

Financial news for NBIX dated on 2019-12-13: Credit Suisse Downgrades Neurocrine Biosciences to Neutral, Announces \$110 Price Target

Financial news for NBIX dated on 2019-12-11: Xenon Pharmaceuticals 13D Shows Neurocrine Biosciences Holds 5.4% Stake In Co.

Financial news for NBIX dated on 2019-12-11: Neurocrine Biosciences Shares Fall At Open, Down 6%, As Traders Circulate Word Of Negative Report By Aurelius Value

Financial news for NBIX dated on 2019-12-07: Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at AES 2019

Financial news for NBIX dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for NBIX dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy

Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for NBIX dated on 2019-12-02: Xenon to Receive \$50M Upfront Payment From Neurocrine Biosciences for the Rights to Xenon's XEN901

Financial news for NBIX dated on 2019-11-29: Stocks That Hit 52-Week Highs On Friday

Financial news for NBIX dated on 2019-11-27: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NBIX dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for NBIX dated on 2019-11-25: Stocks That Hit 52-Week Highs On Monday

Financial news for NBIX dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for NBIX dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for NBIX dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for NBIX dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NBIX dated on 2019-11-12: The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

Financial news for NBIX dated on 2019-11-11: Stocks That Hit 52-Week Highs On Monday

Financial news for NBIX dated on 2019-11-05: Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to \$122

Financial news for NBIX dated on 2019-11-04: Neurocrine Biosciences Q3 EPS \$0.56 Misses \$0.64 Estimate, Sales \$222.1M Beat \$211.63M Estimate

Financial news for NBIX dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for NBIX dated on 2019-10-07: Neurocrine Biosciences Late Friday Presented Data Analyses Demonstrating Long-Term Effects of INGREZZA(r) (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Financial news for NBIX dated on 2019-10-01: Neurocrine Biosciences Reports Will Present Data Showing Long-Term Effectiveness of INGREZZA(r) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Financial news for NBIX dated on 2019-10-01: Neurocrine Biosciences To Present Data Analyses Demonstrating The Long-Term Effectiveness Of INGREZZA In Patients With Tardive Dyskinesia At The 2019 Annual Psych Congress Oct. 3-6

Financial news for NBIX dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for NBIX dated on 2019-09-25: UPDATE: Baird's Skorney, When Asked If Neurocrine Shares Rebound Is Related To Traders Circulating Data From A Clinicaltrials.gov Study, Says 'I Don't Think So. The Rebound Seems Pretty Nominal And In-line With The Rest Of The Sector.'

Financial news for NBIX dated on 2019-09-25: Neurocrine Shares Earlier Spiked 1.8% Following Trader Circulation Of ClinicalTrials.gov Doc, Price Soon After Pared Gains; Baird's Brian Skorney Tells Benzinga 'This Study Really Shouldn't Have Any Impact On Outlook For NBIX'

Financial news for NBIX dated on 2019-09-25: Neurocrine Biosciences Shares Rebound From Session Low As Traders Circulate ClinicalTrials.gov Study Record Detail Doc For 'Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's Disease (KINECT-HD)'

Financial news for NBIX dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for NBIX dated on 2019-09-17: Neurocrine Biosciences Highlights Will Present Data On INGREZZA For Tardive Dyskinesia, Opicapone, VY-AADC For Parkinson's

At International Congress of Parkinson's Disease and Movement Disorders

Financial news for NBIX dated on 2019-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2019

Financial news for NBIX dated on 2019-08-07: RBC Capital Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces \$118 Price Target

Financial news for NBIX dated on 2019-08-05: AbbVie Submits New Drug Application FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

Financial news for NBIX dated on 2019-08-02: 29 Healthcare Stocks Moving In Friday's After-Market Session

Financial news for NBIX dated on 2019-08-01: 28 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for NBIX dated on 2019-07-31: 80 Biggest Movers From Yesterday

Financial news for NBIX dated on 2019-07-30: 58 Stocks Moving In Tuesday's Mid-Day Session

Financial news for NBIX dated on 2019-07-30: Neurocrine Biosciences shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

Financial news for NBIX dated on 2019-07-30: Credit Suisse Maintains Outperform on Neurocrine Biosciences, Raises Price Target to \$110

Financial news for NBIX dated on 2019-07-30: 33 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for NBIX dated on 2019-07-30: Piper Jaffray Maintains Overweight on Neurocrine Biosciences, Raises Price Target to \$111

Financial news for NBIX dated on 2019-07-30: 42 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NBIX dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for NBIX dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for NBIX dated on 2019-07-29: Neurocrine Biosciences Q2 EPS \$0.54 May Not Compare To \$0.11 Estimate, Sales \$183.58M Beat \$163.14M Estimate

Financial news for NBIX dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for NBIX dated on 2019-07-11: The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

Financial news for NBIX dated on 2019-07-10: Neurocrine Biosciences Announces FDA Acceptance Of New Drug Application For Opicapone As An Adjunctive Treatment For Patients With Parkinson's Disease

Financial news for NBIX dated on 2019-06-11: Neurocrine Biosciences Highlights Will Present Data On INGREZZA, Opicapone At World Congress on Parkinson's Disease and Related Disorders

Financial news for NBIX dated on 2019-06-05: Guggenheim Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces \$88 Price Target

Financial news for NBIX dated on 2019-05-21: Credit Suisse Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock with Outperform Rating, Announces \$95 Price Target

Financial news for NBIX dated on 2019-05-20: Hearing Credit Suisse Initiated Coverage On Neurocrine Biosciences With Outperform Rating, \$95 Price Target

Financial news for NBIX dated on 2019-05-20: Neurocrine Biosciences Highlights Presentation Of New Data From RE-KINECT Showing The Effect Of Involuntary Movements On Patient Quality of Life

Financial news for NBIX dated on 2019-05-16: Neurocrine Biosciences Highlights Presentation Of New Quality-of-Life Data Analysis from RE-KINECT At American

Psychiatric Association Annual Meeting

Financial news for NBIX dated on 2019-05-14: Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug

Financial news for NBIX dated on 2019-05-05: Neurocrine Biosciences, Voyager Therapeutics Announce Treatment with VY-AADC Improved Good ON Time (ON Time Without Troublesome Dyskinesia) by 1.7 Hours and Reduced OFF Time by 2.2 Hours at 12 Months in Patients with Parkinson's Disease

Financial news for NBIX dated on 2019-05-05: Neurocrine Biosciences Announces Phase III Data Showa Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations

Financial news for NBIX dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for NBIX dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for NBIX dated on 2019-04-29: Neurocrine Biosciences shares are trading lower after the company reported lower-than-expected Q1 EPS results.

Financial news for NBIX dated on 2019-04-29: Neurocrine Biosciences Q1 EPS \$(1.12) Misses \$(0.92) Estimate, Sales \$138.403M Beat \$137.03M Estimate

Financial news for NBIX dated on 2019-04-29: Neurocrine Biosciences Option Alert: May 17 \$90 Calls at the Ask: 1000 @ \$0.85 vs 4814 OI; Earnings 4/29 After Close Ref=\$77.44

Financial news for NBIX dated on 2019-04-26: Neurocrine Biosciences Says Express Scripts National Preferred Currently Accounts For Less Than One Percent Of Ingrezza Product Revenue; Continues To Engage With Express Scripts

Financial news for NBIX dated on 2019-04-26: Express Scripts Published Updated 2019 National Preferred Formulary Exclusions List That Will Exclude Ingrezza (Valbenazine); Excluding Is Effective July 1, 2019

Financial news for NBIX dated on 2019-04-26: Neurocrine Biosciences Option Alert: Jun 21 \$80 Calls Sweep (2) near the Bid: 2000 @ \$3.101 vs 13 OI; Earnings 4/29 After Close Ref=\$74.24

Financial news for NBIX dated on 2019-04-26: Neurocrine Biosciences Shares Fall As Express Scripts Reportedly Excluded Its Drug From Formulary

Financial news for NBIX dated on 2019-04-22: 6 Biggest Price Target Changes For Monday

Financial news for NBIX dated on 2019-04-22: Benzinga's Top Upgrades, Downgrades For April 22, 2019

Financial news for NBIX dated on 2019-04-22: JP Morgan Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to \$106

Financial news for NBIX dated on 2019-04-12: Evercore ISI Group Initiates Coverage On Neurocrine Biosciences with Outperform Rating

Financial news for NBIX dated on 2019-03-28: Neurocrine Biosciences And Voyager Therapeutics Announce Publication Of Phase 1b Trial Results Of VY-AADC For Parkinson's Disease In The Annals Of Neurology

Financial news for NBIX dated on 2019-03-12: Neurocrine Biosciences Reports Interim Results From Phase II Study Of NBI-74788 In Adults With Classic Congenital Adrenal Hyperplasia; Results Showed At Least 50% Reduction From Baseline

Financial news for NBIX dated on 2019-02-06: The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Financial news for NBIX dated on 2019-02-05: Neurocrine Biosciences Sees FY19 Sales Milestones Under AbbVie Deal \$20M; Ongoing SG&A, R&D Expenses Expected \$550M-\$600M

Financial news for NBIX dated on 2019-02-05: Neurocrine Biosciences Q4 EPS \$0.19 Beats \$0.15 Estimate, Sales \$131.492M Beat \$128.11M Estimate

Financial news for NBIX dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for NBIX dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for NBIX dated on 2019-01-29: Neurocrine Biosciences And Voyager Therapeutics Form Strategic Development And Commercialization Collaboration For Parkinson's Disease And Friedreich's Ataxia; Voyager Receives \$165M Upfront, Up To \$1.7B In Milestones

Financial news for NBIX dated on 2019-01-24: Needham Downgrades Neurocrine Biosciences to Hold

Financial news for NBIX dated on 2019-01-23: JP Morgan Downgrades Neurocrine Biosciences to Neutral, Raises Price Target to \$100

Financial news for NBIX dated on 2019-01-16: Neurocrine Biosciences Highlights Analysis Of Its INGREZZA Capsules In The Journal Of Affective Disorders

Financial news for NBIX dated on 2019-01-08: 65 Biggest Movers From Yesterday

Financial news for NBIX dated on 2019-01-07: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for NBIX dated on 2019-01-07: Neurocrine Biosciences shares are trading higher after the company announced it expects Q4 net product sales to have doubled since last year.

Financial news for NBIX dated on 2019-01-06: Neurocrine Biosciences Sees Q4 Net Product Sales \$130M vs \$64.5M YoY; Sees FY 2018 Net Product Sales \$409M vs \$116.6M YoY

Financial news for NBIX dated on 2018-12-13: Goldman Sachs Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces \$103 Price Target

Financial news for NBIX dated on 2018-12-13: 52 Biggest Movers From Yesterday

Financial news for NBIX dated on 2018-12-12: Mid-Afternoon Market Update: Sparton Climbs On Acquisition News; Synergy Pharmaceuticals Shares Slide

Financial news for NBIX dated on 2018-12-12: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NBIX dated on 2018-12-12: Mid-Day Market Update: NASDAQ Rises 2%; Neurocrine Biosciences Shares Plunge

Financial news for NBIX dated on 2018-12-12: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 11, 2018

Financial news for NBIX dated on 2018-12-12: Mid-Morning Market Update: Markets Open Higher; Vera Bradley Misses Q3 Estimates

Financial news for NBIX dated on 2018-12-12: Neurocrine Biosciences are trading steeply lower after the company announced a Phase IIb study did not meet its primary endpoint in Tourette's Syndrome patients.

Financial news for NBIX dated on 2018-12-12: Neurocrine Biosciences Resume Trade, Down 25.8%

Financial news for NBIX dated on 2018-12-12: Neurocrine Biosciences Shares To Resume Trade At 8:00 a.m. ET

Financial news for NBIX dated on 2018-12-12: Neurocrine Biosciences Announces Topline Data From Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint In Pediatric Patients with Tourette Syndrome

Financial news for NBIX dated on 2018-12-12: Neurocrine Biosciences Shares Halted, News Pending

Financial news for NBIX dated on 2018-12-06: Neurocrine Biosciences Option Alert: Dec 21 \$100 Calls Sweep (2) near the Ask: 938 @ \$1.101 vs 546 OI; Ref=\$86.39

Financial news for NBIX dated on 2018-11-21: Benzinga's Top Upgrades, Downgrades For November 21, 2018

Financial news for NBIX dated on 2018-11-21: Canaccord Genuity Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces \$111 Price Target

Financial news for NBIX dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for NBIX dated on 2018-11-15: 76 Biggest Movers From Yesterday

Financial news for NBIX dated on 2018-11-14: AbbVie Reports Presented Phase 3 Data Showing Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress

Financial news for NBIX dated on 2018-11-13: Leerink Swann Initiates Coverage On Neurocrine Biosciences with Market Perform Rating, Announces \$110 Price Target

Financial news for NBIX dated on 2018-11-06: Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to \$135

Financial news for NBIX dated on 2018-11-06: 24 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NBIX dated on 2018-11-05: Neurocrine Biosciences Q3 EPS \$0.52 Beats \$0.46 Estimate, Sales \$151.757M Miss \$151.83M Estimate

Financial news for NBIX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NBIX dated on 2018-10-26: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for NBIX dated on 2018-10-26: 'A New Way To Treat The Brain': Stanford University Scientists Launch Cannabis Pharma Company

Financial news for NBIX dated on 2018-10-09: Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines To Treat Central Nervous System Disorders

Financial news for NBIX dated on 2018-10-01: Neurocrine Biosciences Says Will Present New Long-Term Data Analyses On INGREZZA At International Congress of Parkinson's Disease and Movement Disorders (MDS) in Hong Kong, Oct. 5-9, 2018

Financial news for NBIX dated on 2018-09-20: Stifel Nicolaus Maintains Buy on Neurocrine Biosciences, Raises Price Target to \$142

Financial news for NBIX dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for NBIX dated on 2018-09-10: A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others

Financial news for NBIX dated on 2018-09-10: Benzinga's Top Upgrades, Downgrades For September 10, 2018

Financial news for NBIX dated on 2018-09-10: Morgan Stanley Initiates Coverage On Neurocrine Biosciences with Overweight Rating, Announces \$145 Price Target

Financial news for NBIX dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for NBIX dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for NBIX dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for NBIX dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for NBIX dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for NBIX dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for NBIX dated on 2018-08-28: The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetrphase's Antibiotic

Financial news for NBIX dated on 2018-08-23: Benzinga's Top Upgrades, Downgrades For August 23, 2018

Financial news for NBIX dated on 2018-08-23: Cantor Fitzgerald Initiates Coverage On Neurocrine Biosciences with Overweight Rating, Announces \$150 Price Target

Financial news for NBIX dated on 2018-08-15: Neurocrine Biosciences Will Present

INGREZZA Data At 2018 World Congress On Parkinson's August 19-22

Financial news for NBIX dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for NBIX dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for NBIX dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for NBIX dated on 2018-08-08: Stocks Which Set New 52-Week High Yesterday, August 7th

Financial news for NBIX dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for NBIX dated on 2018-08-07: 4 Reasons Behind Stifel's Neurocrine Bull Thesis

Financial news for NBIX dated on 2018-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2018

Financial news for NBIX dated on 2018-08-07: Stifel Nicolaus Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces \$137 Price Target

Financial news for NBIX dated on 2018-08-03: Stocks Which Set New 52-Week High Yesterday, August 2nd

Financial news for NBIX dated on 2018-08-02: Stocks Which Set New 52-Week High Yesterday, August 1st

Financial news for NBIX dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for NBIX dated on 2018-08-02: 66 Biggest Movers From Yesterday

Financial news for NBIX dated on 2018-08-01: Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to \$135

Financial news for NBIX dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for NBIX dated on 2018-07-31: Neurocrine Biosciences Q2 EPS \$(0.07) Beats \$(0.17) Estimate, Sales \$96.905M Beat \$84.11M Estimate

Financial news for NBIX dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for NBIX dated on 2018-07-26: Stocks Which Set New 52-Week High Yesterday, July 25th

Financial news for NBIX dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for NBIX dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for NBIX dated on 2018-07-25: Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to \$122

Financial news for NBIX dated on 2018-07-24: Neurocrine Biosciences 8-K Highlights FDA Approval Of AbbVie's ORILISSA; Co. To Receive \$40M Event-Based Payment Made By AbbVie

Financial news for NBIX dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for NBIX dated on 2018-07-06: Neurocrine Biosciences Option Alert: Jul 20 \$110 Calls at the Ask: 500 @ \$1.0 vs 382 OI; Earnings 8/2 After Close [est] Ref=\$101.905

Financial news for NBIX dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for NBIX dated on 2018-06-30: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Financial news for NBIX dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's

Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for NBIX dated on 2018-05-31: Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time

Financial news for NBIX dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for NBIX dated on 2018-05-08: UPDATE: Neurocrine Highlights 'New Data from KINECT 4 Study Show Long-Term Treatment with INGREZZA(r) (valbenazine) Capsules Provided Sustained, Clinically Meaningful Improvement in Tardive Dyskinesia and was Well-Tolerated'

Financial news for NBIX dated on 2018-05-08: UPDATE: Neurocrine Says Nearly 28% Of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia

Financial news for NBIX dated on 2018-05-08: Neurocrine Biosciences Reports Presentation Of New Quality Of Life Data From RE-KINECT Study Of Possible Tardive Dyskinesia In Patients Treated with Antipsychotics

Financial news for NBIX dated on 2018-05-01: Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to \$100.00

Financial news for NBIX dated on 2018-05-01: JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to \$103.00

Financial news for NBIX dated on 2018-05-01: Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings

Financial news for NBIX dated on 2018-04-30: Neurocrine Biosciences Raises FY18 Operating Expenses Guidance From \$365-\$395M to \$395M-\$420M

Financial news for NBIX dated on 2018-04-30: Neurocrine Biosciences Q1 EPS \$(0.47) Misses \$(0.31) Est., Sales \$71.1M Beats \$63.79M Est.

Financial news for NBIX dated on 2018-04-10: AbbVie and Neurocrine Biosciences Reports That The FDA Requires Extended Time For Review Of Additional Info In New Drug Application; Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain

Financial news for NBIX dated on 2018-04-10: Abbvie and Neurocrine Biosciences Notified by the FDA that Additional Time is Required to Review Additional Information

Financial news for NBIX dated on 2018-04-03: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Financial news for NBIX dated on 2018-02-15: 13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies

Financial news for NBIX dated on 2018-02-14: Neurocrine Biosciences Will File NDA For Opicapone in 1H19

Financial news for NBIX dated on 2018-02-14: JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises price target to \$100.00

Financial news for NBIX dated on 2018-02-13: Neurocrine Biosciences Reports Q4 EPS \$0.07 vs \$0.18 Est., Sales \$94.5M vs \$87M Est.

Financial news for NBIX dated on 2018-01-23: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for NBIX dated on 2018-01-08: Neurocrine Bioscience Option Alert: Dec, 2018 \$70 Puts at the Ask: 750 @ \$8.801 vs 0 OI; Earnings 2/13 After Close [est] Ref=\$77.87

Financial news for NBIX dated on 2018-01-08: Neurocrine Biosciences Saturday Announced CMO Christopher O'Briend Retriring, Eiry Roberts To Assume Position

Financial news for NBIX dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for NBIX dated on 2018-01-07: Neurocrine Biosciences Reports Preliminary Q4 Sales ~\$94M vs \$76.09M Est; FY 2017 Sales ~\$161M vs \$143.17M Est

Financial news for NBIX dated on 2017-12-18: Neurocrine Bioscience Option Alert: Feb 16 \$60 Puts Sweep (11) at the Bid: 600 @ \$1.0 vs 229 OI; Ref=\$70.33

Financial news for NBIX dated on 2017-12-04: Neurocrine Biosciences Presents New Long-Term Data From KINECT 4 Phase III Open-Label Study, Shows INGREZZA Improved Symptoms Through 48 Wks

Financial news for NBIX dated on 2017-11-20: Neurocrine Biosciences Names Matt Abernethy CFO

Financial news for NBIX dated on 2017-11-14: Neurocrine Reports Long-Term Results Evaluating INGREZZA for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry

Financial news for NBIX dated on 2017-11-03: 66 Biggest Movers From Yesterday

Financial news for NBIX dated on 2017-11-02: Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch

Financial news for NBIX dated on 2017-11-02: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for NBIX dated on 2017-11-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for NBIX dated on 2017-11-01: Neurocrine Q3 EPS \$(0.13) vs \$(0.49) Est., Sales \$60.77M vs 29.86M Est., May Not Compare

Financial news for NBIX dated on 2017-11-01: AbbVie Announces 'Positive' Phase 3 Extension Study Data For Elagolix

Financial news for NBIX dated on 2017-10-25: Neurocrine Starts Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome

Financial news for NBIX dated on 2017-10-23: Neurocrine Biosciences Granted FDA Orphan Drug Designation For Valbenazine

Financial news for NBIX dated on 2017-10-05: A Peek Into The Markets: U.S. Stock Futures Flat Ahead Of Fed Speakers, Economic Data

Financial news for NBIX dated on 2017-10-05: Neurocrine Biosciences Reports FDA Approval Of 80mg INGREZZA Capsules For Treatment Of Adults With TD

Financial news for NBIX dated on 2017-09-28: Attention Biotech Investors, Here's Your PDUFA Primer For October

Financial news for NBIX dated on 2017-09-11: Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers

Financial news for NBIX dated on 2017-08-25: Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments

Financial news for NBIX dated on 2017-08-03: Neurocrine Biosciences Reports Q2 EPS \$(0.68) vs \$(0.66) Est., Sales \$6.3M vs \$660K Est.

Financial news for NBIX dated on 2017-07-05: Neurocrine Biosciences Submitted a Supplemental NDA to the FDA for Ingrezza

Financial news for NBIX dated on 2017-06-27: Neurocrine Biosciences Spikes to High of \$47.34 on Volume

Financial news for NBIX dated on 2017-05-31: Reminder: Neurocrine Biosciences Phase II Ingrezza Study Results Expected By End Of May

Financial news for NBIX dated on 2017-05-24: Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out

Financial news for NBIX dated on 2017-05-24: 15 Biggest Mid-Day Losers For Wednesday

Financial news for NBIX dated on 2017-05-24: BMO on Neurocrine Biosciences: 'Buy on the Weakness'; Maintains Outperform Rating, \$75 Price Target

Financial news for NBIX dated on 2017-05-23: Neurocrine Reports Phase II Results of INGREZZA for Treatment of Tourette Syndrome: Did Not Meet Primary Endpoint

Financial news for NBIX dated on 2017-05-22: Companies Holding Shareholder Meetings

Today Include: Morgan Stanley, Neurocrine Biosciences, DeVry Education, Twitter, Summer Infant, & Royal Caribbean Cruises

Financial news for NBIX dated on 2017-05-17: Bank Of America Health Care Conference Continues Today; Presenters Include Celgene, Ionis, Neurocrine Biosciences, Cigna, GW Pharma, Allergan, Ironwood Pharma, Tenet Healthcare, Civitas Solutions, & Amgen

Financial news for NBIX dated on 2017-05-09: Neurocrine Biosciences Reports Q1 EPS \$(0.90) vs \$(0.74) Est.

Financial news for NBIX dated on 2017-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2017

Financial news for NBIX dated on 2017-05-05: Bank of America Initiates Coverage On Neurocrine Biosciences with Buy Rating, Announces \$70.00 Price Target

Financial news for NBIX dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for NBIX dated on 2017-04-21: Neurocrine Announces INGREZZA Long-Term Safety and Efficacy Data to be Presented at the AAN 2017

Financial news for NBIX dated on 2017-04-13: The Market In 5 Minutes

Financial news for NBIX dated on 2017-04-12: Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over Teva

Financial news for NBIX dated on 2017-04-12: Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside

Financial news for NBIX dated on 2017-04-12: 11 Biggest Mid-Day Gainers For Wednesday

Financial news for NBIX dated on 2017-04-12: Martin Shkreli on Facebook Posts '\$NBIX juicy short'

Financial news for NBIX dated on 2017-04-12: Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval

Financial news for NBIX dated on 2017-04-12: 19 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NBIX dated on 2017-04-12: Hearing BMO Out Positive On Neurocrine, Says Positive Ingrezza Label, Coupled With Other Catalysts, Opens Pathway For Greater Than \$100/Share Stock

Financial news for NBIX dated on 2017-04-12: Neurocrine Biosciences +24.1% Preamarket @ \$51.50; Co Announced FDA Approval of INGREZZA on Tuesday

Financial news for NBIX dated on 2017-04-11: CNBC's Meg Tirrell Recently Tweets '\$NBIX says it "will announce pricing concurrent with launch and the deployment of its sales reps in May"'

Financial news for NBIX dated on 2017-04-11: Neurocrine Biosciences Shares Resume, Now Up ~14%

Financial news for NBIX dated on 2017-04-11: Adam Feuerstein Tweets: \$NBIX says no black box safety warning for Ingrezza. That's an added positive in competitive fight against \$TEVA.

Financial news for NBIX dated on 2017-04-11: Neurocrine Shares to Resume Trade at 5:25 p.m. EDT

Financial news for NBIX dated on 2017-04-11: UPDATE: Neurocrine To Host Investor Conf. Call, Webcast Scheduled For Today At 5:30pm ET

Financial news for NBIX dated on 2017-04-11: Neurocrine Reports FDA Approval of INGREZZA TM

Financial news for NBIX dated on 2017-04-11: Neurocrine Biosciences Halted News Pending

Financial news for NBIX dated on 2017-04-11: Neurocrine Biosciences Shares Up Nearly 2% Over Last Few Mins; BZ NOTE: Co. Has Discussion with FDA Panel/PDUFA Date Today

Financial news for NBIX dated on 2017-04-11: Neurocrine Biosciences INGREZZA Has FDA PDUFA Date Today

Financial news for NBIX dated on 2017-03-24: Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive

Financial news for NBIX dated on 2017-03-21: Neurocrine Reports Kinect 3 Phase 3 Study of INGREZZA for Treatment of Tardive Dyskinesia Shows 'significant and meaningful reduction in symptoms'

Financial news for NBIX dated on 2017-03-21: Neurocrine Reports American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM for the Treatment of Tardive Dyskinesia

Financial news for NBIX dated on 2017-02-14: Neurocrine Biosciences Reports Q4 EPS \$(0.51) vs \$(0.56) Est.

Financial news for NBIX dated on 2017-02-09: Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone, Neurocrine Will Make Upfront Payment Of \$30M, Fund All Development To Get FDA Approval

Financial news for NBIX dated on 2017-01-27: 15 Biggest Mid-Day Gainers For Friday

Financial news for NBIX dated on 2017-01-27: Benzinga's Top Upgrades, Downgrades For January 27, 2017

Financial news for NBIX dated on 2017-01-27: Oppenheimer Upgrades Neurocrine Biosciences To Outperform

Financial news for NBIX dated on 2017-01-18: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NBIX dated on 2017-01-18: Neurocrine Biosciences Shares Down 5% Premarket Following News Late Tues. Showing Pre-Specified Primary Endpoint at Week 8 Not Met

Financial news for NBIX dated on 2017-01-13: 7 Biotech Catalysts Remaining In January

Financial news for NBIX dated on 2017-01-06: 15 Biggest Mid-Day Gainers For Friday

Financial news for NBIX dated on 2017-01-06: Neurocrine Biosciences Announces David Alexandre Gros COO

Financial news for NBIX dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for NBIX dated on 2017-01-05: Neurocrine Provides Update on FDA Advisory Committee for INGREZZA for the Treatment of Tardive Dyskinesia

Financial news for NBIX dated on 2017-01-05: Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'

Financial news for NBIX dated on 2016-12-21: Neurocrine Biosciences CFO Timothy P. Coughlin to Step Down

Financial news for NBIX dated on 2016-12-14: BMO Capital Healthcare Conf. Takes Place Today; Presenters Include Neurocrine Biosciences, Ionis Pharmaceuticals, Horizon Pharma, And Intercept Pharmaceuticals

Financial news for NBIX dated on 2016-12-09: 10 Stocks With Lowest Close In Three Weeks

Financial news for NBIX dated on 2016-12-08: Neurocrine Biosciences Shares Down 4.54% Midday On Above Average Volume

Financial news for NBIX dated on 2016-12-08: Martin Shkreli Tweets: \$NBIX definitely not a long in my brief (and dangerous) view. company did a good job rescuing itself on this drug but hard to see it sell

Financial news for NBIX dated on 2016-12-08: Neurocrine Biosciences Shares Down 4.42% Midday On Above Average Volume

Financial news for NBIX dated on 2016-11-29: Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA New Drug Application for the Treatment of Tardive Dyskinesia

Financial news for NBIX dated on 2016-11-23: 6 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for NBIX dated on 2016-11-22: Oppenheimer Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock at Perform, Announces \$55.00 Target

Financial news for NBIX dated on 2016-11-03: Deutsche Bank Initiates Coverage On

Neurocrine Biosciences, Inc. - Common Stock at Buy

Financial news for NBIX dated on 2016-11-02: Neurocrine Biosciences Reports Q3 EPS \$(0.43) vs. Est. \$(0.57)

Financial news for NBIX dated on 2016-10-19: AbbVie Reports Elagolix Shows Superiority To Placebo In Reducing Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis, FDA NDA Anticipated in 2017

Financial news for NBIX dated on 2016-10-19: Abbvie/Neurocrine Biosciences Phase 3 Elagolix Trial Data Expected To Be Presented At American Society For Reproductive Medicine Mtg

Financial news for NBIX dated on 2016-10-18: Benzinga's Top Initiations

Financial news for NBIX dated on 2016-10-18: Needham Initiates Coverage On Neurocrine Biosciences, Inc. - Common Stock at Buy, Announces \$62.00

Financial news for NBIX dated on 2016-10-11: Neurocrine Announces INGREZZA NDA for Treatment of Tardive Dyskinesia has been Accepted for Priority Review by FDA

Financial news for NBIX dated on 2016-10-11: Neurocrine Biosciences New Drug Application Accepted for Review by FDA

Financial news for NBIX dated on 2016-10-04: Leerink Swann Assumes Neurocrine Biosciences at Outperform, Announces \$70.00 PT

Financial news for NBIX dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for NBIX dated on 2016-08-31: Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA for VMAT2 Inhibitor Valbenazine

Financial news for NBIX dated on 2016-08-29: Neurocrine Submits NDA for Valbenazine for Treatment of Tardive Dyskinesia

Financial news for NBIX dated on 2016-07-28: Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome

Financial news for NBIX dated on 2016-06-29: Benzinga's Top Initiations

Financial news for NBIX dated on 2016-06-29: H.C. Wainwright Initiates Coverage on Neurocrine Biosciences at Buy, Announces \$80.00 PT

Financial news for NBIX dated on 2016-05-20: Neurocrine Biosciences' Board Member, Thomas Mitchell Retires

Financial news for NBIX dated on 2016-05-06: Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting

Financial news for NBIX dated on 2016-05-05: Neurocrine Biosciences Reports Q1 EPS \$(0.22) Vs Est \$(0.29), \$15M Vs Est \$15.43M

Financial news for NBIX dated on 2016-04-19: Option Alert: NBIX Jun16 50.0 Calls Sweep: 1239 @ ASK \$3.00: 1239 traded vs 1354 OI: Earnings 5/5 \$46.05 Ref

Financial news for NBIX dated on 2016-04-07: BMO Capital Initiates Coverage on Neurocrine Biosciences at Outperform

Financial news for NBIX dated on 2016-03-03: Neurocrine Bioscience +6% After-Hours @\$38.50

Financial news for NBIX dated on 2016-03-02: Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016

Financial news for NBIX dated on 2016-02-11: Neurocrine Biosciences Reports Q4 EPS \$(0.34) vs \$(0.32) Est.; Sees FY16 Cash Burn ~\$135M-\$145M

Financial news for NBIX dated on 2016-02-10: Mid-Day Market Update: Akamai Technologies Surges On Earnings Beat; KapStone Paper and Packaging Shares Drop

Financial news for NBIX dated on 2016-02-02: Neurocrine Begins Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome

Financial news for NBIX dated on 2016-01-28: AbbVie Initiates Enrollment For Phase 3 Clinical Program For Elagolix Patients With Uterine Fibroids

Financial news for NBIX dated on 2015-12-16: Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome

Financial news for NBIX dated on 2015-12-02: Icahn School Of Medicine At Mount Sinai Files Complaint Against Neurocrine Sciences For Breach Of Contract - 8-K Filings

Financial news for NBIX dated on 2015-11-04: Neurocrine Biosciences Reports Expansion of its Clinical Pipeline

Financial news for NBIX dated on 2015-10-29: Neurocrine Reports Q3 Loss of \$0.40/Share vs Loss \$0.25/Share Est.

Financial news for NBIX dated on 2015-10-20: Neurocrine Bioscience Reports Initiation of Phase I Study of NBI-98854 in Adults with Tourette Syndrome

Financial news for NBIX dated on 2015-10-08: Hearing PiperJaffray Raising Neurocrine Bioscience PT To \$96 From \$86

Financial news for NBIX dated on 2015-10-08: Benzinga's Volume Movers

Financial news for NBIX dated on 2015-10-08: Morning Market Gainers

Financial news for NBIX dated on 2015-10-08: Benzinga's Top #PreMarket Gainers

Financial news for NBIX dated on 2015-10-08: Neurocrine Biosciences +28% Premarket as Phase III Kinect Trial of NBI-98854 Met Primary Endpoint

Financial news for NBIX dated on 2015-10-08: US Stock Futures Down Ahead Of Fed Minutes

Financial news for NBIX dated on 2015-10-08: UPDATE: Neurocrine Says Phase III Kinect Trial of NBI-98854 Met Primary Endpoint; Submission of NDA Planned for '16

Financial news for NBIX dated on 2015-10-08: Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia

Financial news for NBIX dated on 2015-09-30: Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors

Financial news for NBIX dated on 2015-09-16: AbbVie Offers Plans to Proceed to Phase 3 Evaluation of Elagolix

Financial news for NBIX dated on 2015-09-03: Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors

Financial news for NBIX dated on 2015-08-25: Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

Financial news for NBIX dated on 2015-08-25: What Should Biotech Investors Do Now?

Financial news for NBIX dated on 2015-08-13: Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study

Financial news for NBIX dated on 2015-07-29: Neurocrine Biosciences Reports Q2 EPS \$(0.28) vs. Est. \$(0.29)

Financial news for NBIX dated on 2015-07-21: Leerink Swann Assumes Neurocrine Biosciences at Outperform

Financial news for NBIX dated on 2015-06-09: Morning Market Losers

Financial news for NBIX dated on 2015-06-09: Benzinga's Top #PreMarket Losers

Financial news for NBIX dated on 2015-06-09: Aeropostale, SouFun, Cyberark Led Monday's After-Hours Movers

Financial news for NBIX dated on 2015-06-08: Neurocrine Biosciences Shares Fall 14% After-Hours on News Company Halted Clinical Studies of NBI-77860

Financial news for NBIX dated on 2015-06-08: UPDATE: Neurocrine Reports Suspension of Two Planned Clinical Studies of Co.'s CRF Antagonist NBI-77860

Financial news for NBIX dated on 2015-06-08: Neurocrine Biosciences Gives Update on NBI-77860 Program for Congenital Adrenal Hyperplasia

Financial news for NBIX dated on 2015-06-02: Neurocrine Biosciences, Inc. Reports Eric Benevich As Chief Commercial Officer

Financial news for NBIX dated on 2015-04-30: Neurocrine Biosciences Reports Q1 Loss of \$0.01/Share

Financial news for NBIX dated on 2015-04-01: Neurocrine Biosciences, Mitsubishi Tanabe Pharma Announce Agreement to Develop NBI-98854 in Japan, Other Asian Markets

Financial news for NBIX dated on 2015-03-19: JP Morgan Initiates Neurocrine Biosciences With Overweight

Financial news for NBIX dated on 2015-03-19: Benzinga's Top Initiations

Financial news for NBIX dated on 2015-03-19: JP Morgan Initiates Coverage on Neurocrine Biosciences at Overweight, Announces \$54.00 PT

Financial news for NBIX dated on 2015-03-04: Barclays Expands Coverage To 7 New Biotech Stocks

Financial news for NBIX dated on 2015-03-04: Stocks Hitting 52-Week Highs

Financial news for NBIX dated on 2015-03-04: Barclays Initiates Coverage on Neurocrine Biosciences at Overweight, Announces \$60.00 PT

Financial news for NBIX dated on 2015-02-19: UPDATE: Neurocrine Biosciences Prices 6.94M Shares at \$36/Share, Expecting Gross Proceeds \$250M

Financial news for NBIX dated on 2015-02-19: Neurocrine Biosciences Prices 6.944M Share Offering @ \$36.00/Share

Financial news for NBIX dated on 2015-02-18: Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals

Financial news for NBIX dated on 2015-02-17: Neurocrine Biosciences Announces Proposed \$225M Common Stock Offering

Financial news for NBIX dated on 2015-01-20: Neurocrine Biosciences Reports Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO '15

Financial news for NBIX dated on 2015-01-16: Press Release Confirms Neurocrine Biosciences Granted Orphan Drug Status for NBI-77860

Financial news for NBIX dated on 2015-01-15: Stocks Hitting 52-Week Highs

Financial news for NBIX dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for NBIX dated on 2015-01-08: Shares Of Neurocrine Move Higher Following Deutsche Bank Price Target Raise to \$35.00/share

Financial news for NBIX dated on 2015-01-08: Mid-Morning Market Update: Markets Jump; Family Dollar Profit Misses Estimates

Financial news for NBIX dated on 2015-01-08: Benzinga's Volume Movers

Financial news for NBIX dated on 2015-01-08: Stocks Hitting 52-Week Highs

Financial news for NBIX dated on 2015-01-08: Morning Market Gainers

Financial news for NBIX dated on 2015-01-08: Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

Financial news for NBIX dated on 2015-01-08: Neurocrine Biosciences Shares Rise 20% Premarket Following Announcement of Positive Top-Line Results From Phase 3 Study of Elagolix

Financial news for NBIX dated on 2015-01-08: Benzinga's Top #PreMarket Gainers

Financial news for NBIX dated on 2015-01-08: UPDATE: AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix

Financial news for NBIX dated on 2015-01-02: What Investors Expect From Neurocrine Biosciences' Next Drug Announcement

Financial news for NBIX dated on 2014-12-10: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline

Financial news for NBIX dated on 2014-12-10: Neurocrine Biosciences Reports Expansion of Clinical Pipeline

Financial news for NBIX dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for NBIX dated on 2014-11-04: Neurocrine Biosciences Appoints Darin Lippoldt As Chief Legal Officer

Financial news for NBIX dated on 2014-11-03: Neurocrine Biosciences, Inc. Reports Q3 EPS of \$(0.21), Inline

Financial news for NBIX dated on 2014-10-30: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia

Financial news for NBIX dated on 2014-10-20: UPDATE: Neurocrine Reports Topline Efficacy Data During 2H of 2015, Expecting to File NDA in 2H of 2016

Financial news for NBIX dated on 2014-10-20: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854

Financial news for NBIX dated on 2014-10-02: Neurocrine Initiates Tourette Syndrome Clinical Trial

Financial news for NBIX dated on 2014-04-30: Neurocrine Biosciences, Inc. Reports Q1 EPS of \$(0.17) vs \$(0.19) Est

Financial news for NBIX dated on 2014-02-27: US Stock Futures Tumble Ahead Of Durable-Goods Orders, Jobless Claims Data

Financial news for NBIX dated on 2014-02-27: Neurocrine Biosciences Prices 8M Share Offering at \$17.75/Share

Financial news for NBIX dated on 2014-02-25: Neurocrine Files KINECT 1 Study Reanalysis Results in SEC Filing

Financial news for NBIX dated on 2014-02-25: Neurocrine Biosciences Announces 7M Share Offering of Common Stock

Financial news for NBIX dated on 2014-02-06: CORRECTION: Neurocrine Biosciences, Inc. Reports Q4 Loss of \$0.16/Share, Sales \$700K; Sees FY14 Net Loss of \$0.82-0.90/Share

Financial news for NBIX dated on 2014-01-09: UPDATE: Neurocrine Says NBI-98854 Showed Meaningful Reduction

Financial news for NBIX dated on 2014-01-09: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854

Financial news for NBIX dated on 2014-01-08: UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

Financial news for NBIX dated on 2014-01-08: Benzinga's Top #PreMarket Losers

Financial news for NBIX dated on 2014-01-08: Nomura Initiates Coverage on Neurocrine Biosciences, Inc. at Buy, Announces \$23.00 PT

Financial news for NBIX dated on 2014-01-08: Morgan Stanley Downgrades Neurocrine Biosciences, Inc. to Equal-weight, Raises to \$16.00

Financial news for NBIX dated on 2014-01-07: Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report

Financial news for NBIX dated on 2014-01-07: Neurocrine Biosciences CEO to Appear CNBC StreetSigns Between 2:00 PM-3:00 PM

Financial news for NBIX dated on 2014-01-07: Mid-Morning Market Update: Markets Open Higher; IHS Profit Beats Estimates

Financial news for NBIX dated on 2014-01-07: Benzinga's Volume Movers

Financial news for NBIX dated on 2014-01-07: Morning Market Movers

Financial news for NBIX dated on 2014-01-07: Deutsche Bank Maintains Buy on Neurocrine Biosciences, Inc., Raises PT to \$25.00

Financial news for NBIX dated on 2014-01-07: Benzinga's Top #PreMarket Gainers

Financial news for NBIX dated on 2014-01-06: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study

Financial news for NBIX dated on 2013-12-19: Piper Jaffray Initiates Coverage on Neurocrine Biosciences, Inc. at Overweight, Announces \$17.00 PT

Financial news for NBIX dated on 2013-10-29: Neurocrine Biosciences, Inc. Reports Q3 EPS of \$(0.17) vs \$(0.20) Est; Revenue of \$729.0K vs \$790.0K Est

Financial news for NBIX dated on 2013-09-19: Kilroy Realty Acquires Premier Del Mar Office Campus for Approximately \$126M

Financial news for NBIX dated on 2013-09-10: Market Wrap For Tuesday, September 10: Once Again, China Moves Markets Higher

Financial news for NBIX dated on 2013-09-10: Mid-Afternoon Market Update: Apple Releases Two New iPhones, SolarCity Rallies on New Contract

Financial news for NBIX dated on 2013-09-10: Mid-Day Market Update: Five Below Shares Gain On Upbeat Results; Urban Outfitters Tumbles

Financial news for NBIX dated on 2013-09-10: Mid-Morning Market Update: Markets Rise; McDonald's Global Same-Store Sales Increase 1.9%

Financial news for NBIX dated on 2013-09-10: Morning Market Losers

Financial news for NBIX dated on 2013-09-10: Benzinga's Top Pre-Market Losers

Financial news for NBIX dated on 2013-09-10: Deutsche Bank Maintains Buy on Neurocrine Biosciences, Inc., Lowers PT to \$18.00

Financial news for NBIX dated on 2013-09-09: Neurocrine Announces Negative Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia; Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET

Financial news for NBIX dated on 2013-09-03: Neurocrine Biosciences Spikes Higher

Financial news for NBIX dated on 2013-08-29: UPDATE: Deutsche Bank Raises PT on Neurocrine Biosciences Ahead of Key Catalysts

Financial news for NBIX dated on 2013-08-21: Cowen & Company Upgrades Neurocrine Biosciences, Inc. to Outperform, Announces \$20.00 PT

Financial news for NBIX dated on 2013-07-25: Neurocrine Biosciences, Inc. Reports Q2 EPS of \$(0.18) vs \$(0.19) Est; Revenue of \$730.0K vs \$760.0K Est

Financial news for NBIX dated on 2013-06-18: UPDATE: Oppenheimer Initiates Coverage on Neurocrine Biosciences on Potential Elagolix Success

Financial news for NBIX dated on 2013-06-18: Oppenheimer Initiates Coverage on Neurocrine Biosciences, Inc. at Outperform, Announces \$16.00 PT

Financial news for NBIX dated on 2013-05-09: Hearing Chatter of Positive Seeking Alpha Report on Neurocrine Biosciences

Financial news for NBIX dated on 2013-05-02: Neurocrine Biosciences, Inc. Reports Q1 EPS of \$(0.18), Inline; Revenue of \$730.0K vs \$1.12M Est

Financial news for NBIX dated on 2013-05-02: Neurocrine Biosciences Says Elagolix Enters Phase IIB for Uterine Fibroids, Says Endometriosis Phase III on Track

Financial news for NBIX dated on 2013-03-27: Neurocrine Biosciences Commences Phase IIB Study of Elagolix in Uterine Fibroids

Financial news for NBIX dated on 2013-02-11: UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Neurocrine Biosciences After Earnings Report

Financial news for NBIX dated on 2013-02-11: Stocks Hitting 52-Week Highs

Financial news for NBIX dated on 2013-02-11: Jefferies Maintains Buy on Neurocrine Biosciences, Inc., Raises PT to \$14.00

Financial news for NBIX dated on 2013-02-08: Neurocrine Biosciences, Inc. Reports Q4 EPS of \$0.14, Up 600% YOY; Revenue of \$21.90M; Guides FY13

Financial news for NBIX dated on 2013-02-08: Earnings Scheduled For February 8, 2013

Financial news for NBIX dated on 2013-02-05: Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further

Financial news for NBIX dated on 2013-02-05: Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, \$11 Price Target, Neurocrine Biosciences with a Buy and \$13 PT, Repros Therapeutics with Buy, \$26 PT

Financial news for NBIX dated on 2012-11-20: Neurocrine Biosciences Files \$150M Stock

Shelf

Financial news for NBIX dated on 2012-10-31: Neurocrine Biosciences Reports Q3 EPS \$-0.05 vs \$-0.05 Est; Revenues \$16.8M vs \$15.8M Est

Financial news for NBIX dated on 2012-10-04: UPDATE: Morgan Stanley Initiates Neurocrine Biosciences at Overweight on Asset Quality

Financial news for NBIX dated on 2012-10-03: Morgan Stanley Initiates Coverage on Neurocrine Biosciences at Overweight, Announces PT of \$12

Financial news for NBIX dated on 2012-10-01: Neurocrine Announces Start of Phase 2B Study of Vmat2 Inhibitor

Financial news for NBIX dated on 2012-07-31: Neurocrine Biosciences Reports Q2 EPS \$-0.01 vs \$-0.03 Est; Revenues \$10.6M vs \$11.00M Est

Financial news for NBIX dated on 2012-06-05: Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis

Financial news for NBIX dated on 2012-05-02: Neurocrine Biosciences Reports Q1 Revenues \$11.3M vs \$10.84M Est

Financial news for NBIX dated on 2012-03-27: Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012

Financial news for NBIX dated on 2012-03-26: UPDATE: Neurocrine Data From One Site Was Removed Due To The Inconsistent And Incorrect Application Of The Efficacy Assessment Protocol.

Financial news for NBIX dated on 2012-03-26: Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia

Financial news for NBIX dated on 2012-03-16: Deutsche Bank Initiates Coverage on Neurocrine Biosciences at Buy, Announces PT of \$15

Financial news for NBIX dated on 2012-03-16: UPDATE: Deutsche Bank Initiates Buy, \$15 PT on Neurocrine

Financial news for NBIX dated on 2012-01-30: Neurocrine Biosciences Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares

Financial news for NBIX dated on 2012-01-25: Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854

Financial news for NBIX dated on 2012-01-19: Neurocrine Biosciences Prices Public Offering of Common Stock at \$8.10 per Share

Financial news for NBIX dated on 2012-01-18: Neurocrine Biosciences Announces Proposed Public Offering of Common Stock; No Amount given

Financial news for NBIX dated on 2011-11-04: Neurocrine Biosciences Spiking Higher on Heavy Volume

Financial news for NBIX dated on 2011-11-02: Are Upcoming Study Results Spurring Insider Buying at Ligand Pharmaceuticals?

Financial news for NBIX dated on 2011-11-01: Jefferies Has Buy on Neurocrine Bio After Earnings

Financial news for NBIX dated on 2011-10-04: Neurocrine Biosciences Receives Second Milestone Payment of \$20 Million Under Abbott Collaboration Agreement

Financial news for NBIX dated on 2011-09-19: Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment in Second Phase II Clinical Trial

Financial news for NBIX dated on 2011-09-13: Neurocrine Biosciences Announces the Start of Phase II Study of Elagolix in Uterine Fibroids

Financial news for NBIX dated on 2011-08-23: Benzinga's Top Pre-Market Losers

Financial news for NBIX dated on 2011-08-11: Calls Purchased on Neurocrine Biosciences

Financial news for NBIX dated on 2011-07-28: Neurocrine Biosciences Reports Q2 EPS \$0.04 vs \$0.05 Est; Revenues \$12.2M vs \$13.21M Est

Financial news for NBIX dated on 2011-06-24: Jefferies Maintains Buy on Neurocrine Biosciences

Financial news for NBIX dated on 2011-06-23: Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor

Financial news for NBIX dated on 2011-06-07: Technical Trading Summary 6/7/2011

Financial news for NBIX dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for NBIX dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for NBIX dated on 2011-04-06: Jefferies Has Buy Rating On Neurocrine Bio. (NBIX)

Financial news for NBIX dated on 2011-04-05: Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor

Financial news for NBIX dated on 2011-03-28: Jefferies Has Buy Rating On Neurocrine Bio. (NBIX)

Financial news for NBIX dated on 2011-03-25: Piper Jaffray Maintains Overweight on Neurocrine Biosciences (NBIX)

Financial news for NBIX dated on 2011-02-11: Neurocrine Biosciences Up 7.6% On Earnings Beat (NBIX)

Financial news for NBIX dated on 2011-02-11: Hapoalim Sees Strong Upside In Neurocrine Biosciences (NBIX)

Financial news for NBIX dated on 2010-12-22: Neurocrine Biosciences: Marching to 52 Week High (NBIX)

Financial news for NBIX dated on 2010-12-22: Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at \$17.00 a share

Financial news for NBIX dated on 2010-12-15: Best Biotech CEO of 2010 Is...

Financial news for NBIX dated on 2010-12-08: Biotech's Brighter Corners

Financial news for NBIX dated on 2010-12-08: Vote for the Best Biotech CEO of 2010

Financial news for NBIX dated on 2010-12-07: 5 Drug Stock Winners of 2010

Financial news for NBIX dated on 2010-12-06: ETFs For Biotech M&A Mania

Financial news for NBIX dated on 2010-11-23: Jefferies Comments On Neurocrine Bio's Daisy PETAL Study

Financial news for NBIX dated on 2010-11-02: Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Jacobs Engineering, Ford, Kellogg and Honda Motor Co. - Press Releases

Financial news for NBIX dated on 2010-10-28: Neurocrine Biosciences Reports Third Quarter 2010 Results: EPS of \$0.06

Financial news for NBIX dated on 2010-10-18: Neurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials

Financial news for NBIX dated on 2010-09-14: Neurocrine Biosciences Falls on Corticotropin Data (NBIX)

Financial news for NBIX dated on 2010-08-03: Zacks Bull and Bear of the Day Highlights: Neurocrine Biosciences, Big 5 Sporting Goods, Aetna, CVS Caremark and Express Scripts - Press Releases

Financial news for NBIX dated on 2010-08-03: Neurocrine Biosciences (NBIX) - Bull of the Day

Financial news for NBIX dated on 2010-07-29: Hapoalim Securities Reiterates Buy Rating on Neurocrine Biosciences (NBIX)

Financial news for NBIX dated on 2010-07-28: Neurocrine Biosciences Reports Second Quarter 2010 Results

Financial news for NBIX dated on 2010-06-17: Early Volume Plays Among Those Valued Below \$10 (FCH, ABT, NBIX, DSCO)

Financial news for NBIX dated on 2010-06-17: Benzinga's Top Pre-Market Gainers (FSLR, CRUS, NBIX, NVDA)

Financial news for NBIX dated on 2010-06-16: Stocks Hitting 52-Week Highs (SMTS, CRUS, NBIX, ARUN)

Financial news for NBIX dated on 2010-06-16: Mid-Day Market Movers (TLCR, PDO, XFN, NBIX)

Financial news for NBIX dated on 2010-06-16: Benzinga's Top Pre-Market Gainers (SMTS, NBIX, IMMU, CLNE)

Financial news for NBIX dated on 2010-05-26: Mid-Day Market Movers (CJBK, NBIX, MELA, HAFC)

Financial news for NBIX dated on 2010-05-25: Mid-Day Market Movers On The NASDAQ (NBIX, PLBC, RDCM, LJPC)

Financial news for NBIX dated on 2010-05-25: Early Volume Plays Among Those Valued Below \$10 (S, NBIX, AIB, IRE, LYG, NBG)

Financial news for NBIX dated on 2010-05-25: Neurocrine Biosciences (NBIX) All Set To Search For Higher Top

Financial news for NBIX dated on 2010-05-25: Piper Jaffray Upgrades Neurocrine Biosciences to Overweight (NBIX)

Financial news for NBIX dated on 2010-05-25: Benzinga's Top Pre-Market Gainers (NBIX, BSPM, TEVA, HOKU)

Financial news for NBIX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for NBIX dated on 2010-03-05: Potential Volume Plays For March 5, 2010 (CNXT, BRCD, ZANE, NBIX, YMI)

Financial news for NBIX dated on 2010-03-05: Benzinga's Top Pre-Market Losers (MRVL, CNXT, NBIX, SOLF, MENT)

Financial news for NBIX dated on 2009-09-16: Stocks To Watch (OMTR,CKR,NBIX,PPG,RMBS,C)